Nilai Buku saben Saham: CASI Pharmaceuticals, Inc (CASI)

The book value per share chart for CASI Pharmaceuticals (CASI) illustrates the trend of asset accumulation, where 0.00 serves as the current metric level. The issuer's profitability relies on the sale of licensed oncology drugs in China. The growth strategy is based on adapting foreign developments to minimize costs. However, geopolitics and the specifics of Chinese reimbursement create serious financial challenges for the biopharmaceutical business.

Strict price regulations within China's Volume-Based Procurement (VBP) limit the margins of CASI Pharmaceuticals (CASI), rendering the company's assets a key collateral for stability. An analysis of the net book value per share allows for an assessment of residual capital net of liabilities, determining the security's real asset value relative to its market capitalization and the issuer's level of financial security.